Risk Factors for Hypernatremia in Patients with Short- and Long-term Tolvaptan Treatment

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2016 Jul 11

PMID 27395406

Citations 10

Authors

Keita Hirai

Tatsuki Shimomura

Hideaki Moriwaki

Hidetoshi Ishii

Takayuki Shimoshikiryo

Daiki Tsuji

Kazuyuki Inoue

Toshihiko Kadoiri

Kunihiko Itoh

Affiliations

Soon will be listed here.

Abstract

Purpose: The long-term efficacy of tolvaptan, a vasopressin V2 receptor antagonist, has been reported. However, the safety of long-term treatment remains to be fully elucidated. We assessed the safety profile of tolvaptan with respect to hypernatremia.

Methods: This retrospective study included 371 patients treated with tolvaptan. Risk factors for hypernatremia (serum sodium concentration ≥147 mEq/L) were determined.

Results: Hypernatremia occurred in 95 patients (25.6 %), of whom 71 (19.1 %) developed hypernatremia within 7 days of tolvaptan treatment (early onset). Stepwise logistic regression analysis demonstrated that baseline serum sodium ≥140 mEq/L, an initial tolvaptan dosage >7.5 mg, and a BUN/serum creatinine ratio ≥20 were independent risk factors for early onset of hypernatremia. Tolvaptan was prescribed for more than 7 days to 233 patients, of whom 123 were administrated tolvaptan for more than 1 month. Hypernatremia occurred in 24 of these patients (10.3 %) (late onset). Predictive factors for late onset of hypernatremia were an average daily dosage of tolvaptan >7.5 mg and age ≥75 years.

Conclusions: A daily dosage of 7.5 mg or less was recommended to prevent hypernatremia in short- as well as long-term tolvaptan treatment, and mainly elderly patients were at risk for hypernatremia.

Citing Articles

Effect of early administration of tolvaptan on pleural effusion post-hepatectomy.

Iida H, Maehira H, Mori H, Nitta N, Maekawa T, Takebayashi K Langenbecks Arch Surg. 2023; 408(1):406.

PMID: 37845430 DOI: 10.1007/s00423-023-03136-4.

Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats.

Ying Y, Li N, Wang S, Zhang H, Zuo Y, Tang Y Biomedicines. 2023; 11(2).

PMID: 36831143 PMC: 9953117. DOI: 10.3390/biomedicines11020607.

The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.

Ren P, Yang Q Transl Cancer Res. 2022; 10(3):1229-1237.

PMID: 35116450 PMC: 8797353. DOI: 10.21037/tcr-20-2123.

Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.

Fukuoka H, Tachibana K, Shinoda Y, Minamisaka T, Inui H, Ueno K BMC Cardiovasc Disord. 2020; 20(1):467.

PMID: 33121430 PMC: 7597047. DOI: 10.1186/s12872-020-01751-3.

Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report.

Iida H, Maehira H, Mori H, Maekawa T, Tani M Surg Case Rep. 2020; 6(1):61.

PMID: 32232601 PMC: 7105548. DOI: 10.1186/s40792-020-00825-w.

References

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T . OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998; 287(3):860-7. View

Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K . Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2013; 44(1):73-82. DOI: 10.1111/hepr.12098. View

Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K . Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012; 60(6):462-9. DOI: 10.1016/j.jjcc.2012.09.002. View

Kim S, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J . Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011; 25 Suppl 1:S5-17. DOI: 10.1007/s10557-011-6299-3. View

Overgaard-Steensen C, Ring T . Clinical review: practical approach to hyponatraemia and hypernatraemia in critically ill patients. Crit Care. 2013; 17(1):206. PMC: 4077167. DOI: 10.1186/cc11805. View

Torres V, Meijer E, Bae K, Chapman A, Devuyst O, Gansevoort R . Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011; 57(5):692-9. DOI: 10.1053/j.ajkd.2010.11.029. View

Decaux G, Soupart A, Vassart G . Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008; 371(9624):1624-32. DOI: 10.1016/S0140-6736(08)60695-9. View

Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K . Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013; 53(12):1277-85. PMC: 4258069. DOI: 10.1002/jcph.197. View

10.

Matsuzaki M, Hori M, Izumi T, Fukunami M . Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 25 Suppl 1:S33-45. DOI: 10.1007/s10557-011-6304-x. View

11.

Udelson J, McGrew F, Flores E, Ibrahim H, Katz S, Koshkarian G . Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007; 49(22):2151-9. DOI: 10.1016/j.jacc.2007.01.091. View

12.

Gheorghiade M, Gattis W, OConnor C, Adams Jr K, Elkayam U, Barbagelata A . Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291(16):1963-71. DOI: 10.1001/jama.291.16.1963. View

13.

Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J . The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2015; 20(6):633-42. DOI: 10.1007/s10741-015-9503-x. View

14.

Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K . The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res. 2013; 40(6):2381-93. DOI: 10.1177/030006051204000637. View

15.

Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K . Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014; 78(4):844-52. View

16.

Kida K, Shibagaki Y, Tominaga N, Matsumoto N, Akashi Y, Miyake F . Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study. Clin Pharmacokinet. 2014; 54(3):273-84. DOI: 10.1007/s40262-014-0194-6. View

17.

Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A . Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011; 25 Suppl 1:S57-65. DOI: 10.1007/s10557-011-6349-x. View

18.

Konstam M, Gheorghiade M, Burnett Jr J, Grinfeld L, Maggioni A, Swedberg K . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297(12):1319-31. DOI: 10.1001/jama.297.12.1319. View

19.

Imamura T, Kinugawa K, Ohtani T, Sakata Y, Higo T, Kinugawa S . Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study. Int Heart J. 2014; 55(3):264-7. DOI: 10.1536/ihj.13-326. View

20.

Dohi K, Ito M . Novel diuretic strategies for the treatment of heart failure in Japan. Circ J. 2014; 78(8):1816-23. DOI: 10.1253/circj.cj-14-0592. View